These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1962596)

  • 1. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study.
    Abe O
    Am J Clin Oncol; 1991; 14 Suppl 2():S40-5. PubMed ID: 1962596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European early phase II dose-finding study of droloxifene in advanced breast cancer.
    Bellmunt J; Solé L
    Am J Clin Oncol; 1991; 14 Suppl 2():S36-9. PubMed ID: 1962595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group.
    Deschênes L
    Am J Clin Oncol; 1991; 14 Suppl 2():S52-5. PubMed ID: 1962599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of droloxifene in patients with metastatic breast cancer.
    Buzdar AU; Kau S; Hortobagyi GN; Theriault RL; Booser D; Holmes FA; Walters R; Krakoff IH
    Cancer Chemother Pharmacol; 1994; 33(4):313-6. PubMed ID: 8281625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial.
    Bruning PF
    Eur J Cancer; 1992; 28A(8-9):1404-7. PubMed ID: 1515258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
    Buzdar A; Hayes D; El-Khoudary A; Yan S; Lønning P; Lichinitser M; Gopal R; Falkson G; Pritchard K; Lipton A; Wolter K; Lee A; Fly K; Chew R; Alderdice M; Burke K; Eisenber P;
    Breast Cancer Res Treat; 2002 May; 73(2):161-75. PubMed ID: 12088118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
    Pyrhönen S; Valavaara R; Heikkinen M; Rissanen P; Blanco G; Nordman E; Holsti LR; Hajba A
    J Steroid Biochem; 1990 Jun; 36(3):227-8. PubMed ID: 2142239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].
    Chevallier B; Spielmann M; Marty M; Serin D; Pouillart P; Tubiana Hulin M; Mignot L; Pujade Lauraine E; Krams M; Mertens H
    Bull Cancer; 1993 Jul; 80(7):624-8. PubMed ID: 8204943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droloxifene, a new antiestrogen: its role in metastatic breast cancer.
    Rauschning W; Pritchard KI
    Breast Cancer Res Treat; 1994; 31(1):83-94. PubMed ID: 7981460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of toremifene.
    Tominaga T; Abe O; Izuo M; Nomura Y
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S27-9. PubMed ID: 2149281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.
    Haarstad H; Gundersen S; Wist E; Raabe N; Mella O; Kvinnsland S
    Acta Oncol; 1992; 31(4):425-8. PubMed ID: 1632978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical data for Droloxifene.
    Hasmann M; Rattel B; Löser R
    Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.
    Haarstad H; Lønning PE; Gundersen S; Wist E; Raabe N; Kvinnsland S
    Acta Oncol; 1998; 37(4):365-8. PubMed ID: 9743458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.
    Hietanen T; Baltina D; Johansson R; Numminen S; Hakala T; Helle L; Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S37-40. PubMed ID: 2149284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study].
    Aoyama H; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 May; 25(6):853-65. PubMed ID: 9617324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients.
    Grill HJ; Pollow K
    Am J Clin Oncol; 1991; 14 Suppl 2():S21-9. PubMed ID: 1962593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
    Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
    Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
    Gundersen S
    J Steroid Biochem; 1990 Jun; 36(3):233-4. PubMed ID: 2142241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
    Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
    Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trials with toremifene in advanced breast cancer: a review.
    Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.